Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Hearing Disorders: HELP
Articles by Michel Kalamarides
Based on 5 articles published since 2010
(Why 5 articles?)
||||

Between 2010 and 2020, M. Kalamarides wrote the following 5 articles about Hearing Disorders.
 
+ Citations + Abstracts
1 Review Neurofibromatosis type 2: Hearing preservation and rehabilitation. 2018

Jia, H / El Sayed, M M El / Smail, M / Mosnier, I / Wu, H / Sterkers, O / Kalamarides, M / Bernardeschi, D. ·Inserm, UMRS 1159, "unité de réhabilitation chirurgicale mini-invasive robotisée de l'audition", Sorbonne Universités, université Pierre et Marie-Curie Paris 6, 75013 Paris, France; Service d'ORL, otologie, implants auditifs et chirurgie de la base du crâne, GHU Pitié Salpêtrière, AP-HP, 75651 Paris, France; Department of Otolaryngology Head and Neck Surgery, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, 200011 Shanghai, PR China; Sino-French Joint Clinical Research Center of Otology and Neuro-otology, 200011 Shanghai, PR China. · Inserm, UMRS 1159, "unité de réhabilitation chirurgicale mini-invasive robotisée de l'audition", Sorbonne Universités, université Pierre et Marie-Curie Paris 6, 75013 Paris, France; CMR neurofibromatosis type 2, GHU Pitié Salpêtrière, AP-HP, 75651 Paris, France. · Inserm, UMRS 1159, "unité de réhabilitation chirurgicale mini-invasive robotisée de l'audition", Sorbonne Universités, université Pierre et Marie-Curie Paris 6, 75013 Paris, France; CMR neurofibromatosis type 2, GHU Pitié Salpêtrière, AP-HP, 75651 Paris, France; Service d'ORL, otologie, implants auditifs et chirurgie de la base du crâne, GHU Pitié Salpêtrière, AP-HP, 75651 Paris, France. · CMR neurofibromatosis type 2, GHU Pitié Salpêtrière, AP-HP, 75651 Paris, France; Service d'ORL, otologie, implants auditifs et chirurgie de la base du crâne, GHU Pitié Salpêtrière, AP-HP, 75651 Paris, France. · Department of Otolaryngology Head and Neck Surgery, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, 200011 Shanghai, PR China. Electronic address: wuhao622@sina.cn. · Inserm, UMRS 1159, "unité de réhabilitation chirurgicale mini-invasive robotisée de l'audition", Sorbonne Universités, université Pierre et Marie-Curie Paris 6, 75013 Paris, France; CMR neurofibromatosis type 2, GHU Pitié Salpêtrière, AP-HP, 75651 Paris, France; Service d'ORL, otologie, implants auditifs et chirurgie de la base du crâne, GHU Pitié Salpêtrière, AP-HP, 75651 Paris, France; Sino-French Joint Clinical Research Center of Otology and Neuro-otology, 200011 Shanghai, PR China. · CMR neurofibromatosis type 2, GHU Pitié Salpêtrière, AP-HP, 75651 Paris, France; Service de neurochirurgie, GHU Pitié Salpêtrière, Sorbonne Université, AP-HP, 75651 Paris, France; Sino-French Joint Clinical Research Center of Otology and Neuro-otology, 200011 Shanghai, PR China. Electronic address: michel.kalamarides@aphp.fr. ·Neurochirurgie · Pubmed #30314805.

ABSTRACT: The main manifestation of neurofibromatosis type 2 (NF2) is the development of bilateral vestibular schwannomas (VS). Consequently, one of the most severe functional sequelae is bilateral sensorineural hearing loss, caused by spontaneous tumor progression and/or treatment-related damage (surgery or radiosurgery). Preserving or restoring hearing is still challenging in NF2 no matter the strategy applied to each individual based on the natural history of VS. In this review, the different strategies for hearing preservation or rehabilitation are discussed and illustrated by several cases. A decisional algorithm for NF2 patients with VS is proposed that takes into consideration the tumor size and hearing level.

2 Clinical Trial Conservative management of bilateral vestibular schwannomas in neurofibromatosis type 2 patients: hearing and tumor growth results. 2013

Peyre, Matthieu / Goutagny, Stéphane / Bah, Alpha / Bernardeschi, Daniele / Larroque, Béatrice / Sterkers, Olivier / Kalamarides, Michel. ·AP-HP, Hôpital Beaujon, Department of Neurosurgery, Clichy, France. ·Neurosurgery · Pubmed #23407292.

ABSTRACT: BACKGROUND: As new treatment modalities develop for the management of vestibular schwannomas (VS) in patients with neurofibromatosis type 2, it remains crucial to ascertain the natural history of the disease. OBJECTIVE: To determine the relationship between hearing and tumor growth in patients undergoing conservative VS management. METHODS: Patients harboring bilateral VS with at least 1 year of radiological follow-up were selected. Conservative management was proposed based on the small tumor size and/or serviceable hearing at presentation. Tumor size was calculated by using the 2-component box model and reported as mean tumor diameter. Hearing was evaluated by using pure-tone average and the American Academy of Otololaryngologists and Head and Neck Surgery classification. RESULTS: Forty-six patients harboring 92 VS were included. The mean clinical and radiological follow-up times were 6.0 and 4.2 years, respectively. The mean tumor diameter was 13 mm at presentation and 20 mm at the end of follow-up. Mean tumor growth rate was 1.8 mm/year. During follow-up, 17 patients (37%) underwent surgery for VS. Surgery-free rate for VS was 88% at 5 years. The number of patients with at least 1 serviceable ear was 39 (85%) at presentation and 34 (74%) at the end of follow-up, including 22 (66%) with binaural serviceable hearing maintained. There was no statistical correlation between tumor growth rate and preservation of serviceable hearing. Tumor growth rates and age at presentation were inversely correlated. CONCLUSION: This study illustrates the high variability among neurofibromatosis type 2 patients regarding hearing status and VS growth rate and justifies the choice of initial conservative management in selected cases. ABBREVIATIONS: : AAO-HNS, American Academy of Otololaryngologists and Head and Neck Surgery classificationMTD, mean tumor diameterNF2, neurofibromatosis type 2PTA, pure-tone averageSDS, speech discrimination scoreVS, vestibular schwannomas.

3 Article Surgery of the lateral skull base: a 50-year endeavour. 2019

Zanoletti, E / Mazzoni, A / Martini, A / Abbritti, R V / Albertini, R / Alexandre, E / Baro, V / Bartolini, S / Bernardeschi, D / Bivona, R / Bonali, M / Borghesi, I / Borsetto, D / Bovo, R / Breun, M / Calbucci, F / Carlson, M L / Caruso, A / Cayé-Thomasen, P / Cazzador, D / Champagne, P-O / Colangeli, R / Conte, G / D'Avella, D / Danesi, G / Deantonio, L / Denaro, L / Di Berardino, F / Draghi, R / Ebner, F H / Favaretto, N / Ferri, G / Fioravanti, A / Froelich, S / Giannuzzi, A / Girasoli, L / Grossardt, B R / Guidi, M / Hagen, R / Hanakita, S / Hardy, D G / Iglesias, V C / Jefferies, S / Jia, H / Kalamarides, M / Kanaan, I N / Krengli, M / Landi, A / Lauda, L / Lepera, D / Lieber, S / Lloyd, S L K / Lovato, A / Maccarrone, F / Macfarlane, R / Magnan, J / Magnoni, L / Marchioni, D / Marinelli, J P / Marioni, G / Mastronardi, V / Matthies, C / Moffat, D A / Munari, S / Nardone, M / Pareschi, R / Pavone, C / Piccirillo, E / Piras, G / Presutti, L / Restivo, G / Reznitsky, M / Roca, E / Russo, A / Sanna, M / Sartori, L / Scheich, M / Shehata-Dieler, W / Soloperto, D / Sorrentino, F / Sterkers, O / Taibah, A / Tatagiba, M / Tealdo, G / Vlad, D / Wu, H / Zanetti, D. ·Department of Neuroscience DNS, Otolaryngology Section, Padova University, Padova, Italy. · Department of Neurosurgery, Lariboisière Hospital, University of Paris Diderot, Paris, France. · Gruppo Otologico, Piacenza-Rome, Italy. · Academic Neurosurgery, Department of Neuroscience DNS, University of Padova Medical School, Padova, Italy. · Neurosurgery, Bellaria Hospital, Bologna, Italy. · AP-HP, Groupe Hôspital-Universitaire Pitié-Salpêtrière, Neuro-Sensory Surgical Department and NF2 Rare Disease Centre, Paris, France. · Sorbonne Université, Paris, France. · ENT and Skull-Base Surgery Department, Department of Neurosciences, Ospedale Papa Giovanni XXIII, Bergamo, Italy. · Otolaryngology-Head and Neck Surgery Department, University Hospital of Modena, Italy. · Neurosurgery, Maria Cecilia Hospital, Cotignola (RA), Italy. · Department of Neurosurgery, Julius Maximilians University Hospital Würzburg, Bavaria, Germany. · Department of Otolaryngology-Head and Neck Surgery, Mayo Clinic, Rochester, MN, USA. · Department of Neurologic Surgery, Mayo Clinic, Rochester, MN, USA. · The Department of Otorhinolaryngology, Head & Neck Surgery and Audiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark. · Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. · Department of Neuroscience DNS, Section of Human Anatomy, Padova University, Padova, Italy. · Department of Neuroradiology, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milano, Italy. · Department of Radiation Oncology, University Hospital Maggiore della Carità, Novara, Italy. · Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy. · Unit of Audiology, Department of Clinical Sciences and Community Health, University of Milano, Italy. · Department of Surgery, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milano, Italy. · Department of Neurosurgery, Eberhard Karls University Tübingen, Germany. · Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA. · Department of Otorhinolaryngology, Plastic, Aesthetic and Reconstructive Head and Neck Surgery, "Julius-Maximilians" University Hospital of Würzburg, Bavaria, Germany. · Department of Neurosurgery, Cambridge University Hospital, Cambridge, UK. · Oncology Department, Cambridge University Hospital, Cambridge, UK. · Department of Otolaryngology Head and Neck Surgery, Shanghai Ninh People's Hospital, Shanghai Jiatong University School of Medicine, China. · Department of Neurosciences, King Faisal Specialist Hospital & Research Center, Alfaisal University, College of Medicine, Riyadh, KSA. · ENT & Skull-Base Department, Ospedale Nuovo di Legnano, Legnano (MI), Italy. · Department of Neuro-Otology and Skull-Base Surgery Manchester Royal Infirmary, Manchester, UK. · Department of Neuroscience DNS, Audiology Unit, Padova University, Treviso, Italy. · University Aix-Marseille, France. · Otolaryngology-Head and Neck Surgery Department, University Hospital of Verona, Italy. · Mayo Clinic School of Medicine, Rochester, MN, USA. · Department of Neuro-otology and Skull Base Surgery, Cambridge University Hospital, Cambridge, UK. · ENT Department, Treviglio (BG), Italy. ·Acta Otorhinolaryngol Ital · Pubmed #31130732.

ABSTRACT: -- No abstract --

4 Article Natural history of vestibular schwannomas and hearing loss in NF2 patients. 2018

Peyre, M / Bernardeschi, D / Sterkers, O / Kalamarides, M. ·Service de neurochirurgie, hôpital de La Pitié-Salpêtrière, AP-HP, 75013 Paris, France; Université Pierre-et-Marie-Curie, Paris-VI, 75013 Paris, France. · Service d'otologie, d'otoneurochirurgie et de chirurgie cervico-faciale, hôpital de La Pitié-Salpêtrière, AP-HP, 75013 Paris, France; Université Pierre-et-Marie-Curie, Paris-VI, 75013 Paris, France. · Université Pierre-et-Marie-Curie, Paris-VI, 75013 Paris, France; Université Pierre-et-Marie-Curie, Paris-VI, 75013 Paris, France. · Service de neurochirurgie, hôpital de La Pitié-Salpêtrière, AP-HP, 75013 Paris, France; Université Pierre-et-Marie-Curie, Paris-VI, 75013 Paris, France. Electronic address: michel.kalamarides@psl.aphp.fr. ·Neurochirurgie · Pubmed #26183546.

ABSTRACT: CONTEXT AND OBJECTIVE: Bilateral vestibular schwannomas are the hallmark of neurofibromatosis 2 (NF2), occurring in 95% of patients. These tumors are associated with significant morbidity due to hearing loss, tinnitus, imbalance and facial weakness. As radiosurgery and chemotherapy have been recently introduced in the treatment armamentarium in addition to surgery, a thorough evaluation of vestibular schwannoma natural history is mandatory to determine the role and timing of each treatment modality. METHODS: An exhaustive review of the literature was performed using the PubMed database concerning the natural history of tumor growth and hearing loss in NF2 patients with vestibular schwannomas. RESULTS: Although some aspects of vestibular schwannoma natural history remain uncertain (pattern of tumor growth, mean tumor growth rate), factors influencing growth such as age at presentation and paracrine factors are well established. Studies focusing on the natural history of hearing have highlighted different patterns of hearing loss and the possible role of intralabyrinthine tumors. The polyclonality of vestibular schwannomas in NF2 was recently unveiled, giving a new perspective to their growth mechanisms. CONCLUSION: An uniform evaluation of tumor growth using volumetric evaluation and hearing with standard classifications will ensure the use of common endpoints and should improve the quality of clinical trials as well as foster comparison among studies while ensuring more consistency in decision-making.

5 Article Internal Auditory Canal Decompression for Hearing Maintenance in Neurofibromatosis Type 2 Patients. 2016

Bernardeschi, Daniele / Peyre, Matthieu / Collin, Michael / Smail, Mustapha / Sterkers, Olivier / Kalamarides, Michel. ·*AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Otology, Auditory Implants and Skull Base Surgery Department, Paris, France; ‡Sorbonne Universités, UPMC Université Paris VI, Paris, France; §INSERM UMR-S 1159, Réhabilitation Chirurgicale Mini-invasive et Robotisée de l'audition, Paris, France; ¶AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Neurosurgery Department, Paris, France. ·Neurosurgery · Pubmed #26579965.

ABSTRACT: BACKGROUND: In neurofibromatosis type 2 (NF2), multiple therapeutic options are available to prevent bilateral hearing loss that significantly affects the quality of life of patients. OBJECTIVE: To evaluate the morbidity and functional results of internal auditory canal (IAC) decompression in NF2 patients with an only hearing ear. METHODS: Twenty-one NF2 patients operated on for IAC decompression in a 3-year period with a minimum follow-up of 1 year were included in this retrospective study. They presented unilateral deafness due to previous contralateral vestibular schwannoma removal in 16 patients or contralateral hearing loss due to the tumor in 5 patients. Hearing level was of class A (American Academy of Otolaryngology-Head and Neck Surgery classification) in 7 patients, B in 8 patients, C in 1 patient, and D in 5 patients. Pure-tone average and speech discrimination score evaluations were performed at 6 days, 1 year, and during the follow-up. Eight patients had postoperative chemotherapy. RESULTS: No case of facial nerve palsy was observed. In the early postoperative period; all patients maintained the hearing class of the preoperative period. At 1-year follow-up, all but 3 patients maintained their hearing scores; at last follow-up (mean follow-up, 23 ± 8 months; range, 12-44 months), hearing classes remained stable with only 1 patient worsening from class B to C and 1 patient improving from class D to B. CONCLUSION: Decompression of IAC seems to be a useful procedure for hearing maintenance in NF2 patients, with very low morbidity. Ideal timing and association with chemotherapy should be evaluated in the future. ABBREVIATIONS: FN, facial nerveIAC, internal auditory canalNF2, neurofibromatosis type 2PTA, pure tone averageSDS, speech discrimination scoreVS, vestibular schwannoma.